SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to mixed market reactions following its Q4 earnings beat, as the stock experiences a significant dip despite exceeding revenue and EPS estimates. Community discussion centers on concerns over decelerating subscriber growth and conservative 2026 guidance, alongside the ongoing drama and shareholder sentiment surrounding the proposed Warner Bros. acquisition and its impact on buybacks and future debt.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is a trending topic as anticipation grows for its potential PMDA approval in Japan and its presentation at the J.P. Morgan Healthcare Conference, driving significant community discussion. Investors are actively highlighting the company's innovative Alpha DaRT technology and recent strong clinical data in pancreatic cancer, signaling a potential shift towards increased institutional interest in this transformative oncology player.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as escalating geopolitical tensions, particularly surrounding potential US tariffs on European countries over Greenland, drive a significant 'risk-off' rotation in the markets. The community is actively discussing gold as a premier safe-haven asset, anticipating continued strong upside as investors seek protection against market instability and potential fiat currency debasement. This robust demand is pushing the metal to new highs amidst broader concerns over the US dollar and global economic conditions.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent reports of exceptionally high-grade silver drill results from its Nevada project and a broader surge in precious metals prices. The community is actively discussing continued accumulation by billionaire investor Eric Sprott and the potential for a significant short squeeze, while also noting recent commentary from CEO Diane Garrett regarding the company's capital position. Despite enthusiasm for its vast resources, some caution against its current lack of commercial production amid a rapidly rising valuation.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Holdings Inc

Ondas Holdings is trending following an investor day that revealed significantly raised revenue guidance and prompted numerous analyst price target upgrades, signaling strong confidence in its future trajectory. The community is actively discussing the company's robust position in autonomous systems, anticipating a substantial run fueled by potential defense contracts and strategic acquisitions. Despite broader market volatility, investors view recent dips as buying opportunities, reinforcing the long-term growth outlook in critical defense and communication infrastructure.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending due to recent significant government contract wins, notably with the U.S. Department of Health and Human Services and the U.S. Army, signaling increasing adoption of its enterprise AI solutions within the public sector. The community is actively debating whether these new contracts, combined with its high short interest and new leadership, position the company for a major turnaround despite past financial concerns and ongoing skepticism about its long-term growth trajectory.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing extreme volatility as natural gas prices surge dramatically, driven by recent colder weather forecasts and a significant short squeeze in the underlying commodity. This has led to a substantial decline in KOLD, with traders actively debating buying the dip amidst widespread discussion of the natural gas market's 'widowmaker' reputation. The community remains focused on weather pattern shifts and the sustainability of this rapid price movement, highlighting the inherent high risk of leveraged natural gas ETFs.

Anteris Technologies Global Corp. is a structural heart company, which engages in the development and commercialization of medical devices for heart diseases. It operates through the following geographical segments: United States, Germany, Australia, Switzerland, and Sweden. The company was founded in 1999 and is headquartered in Eagan, MN.

Anteris Technologies Global Corp.

Anteris Technologies Global

Anteris Technologies (AVR) is currently trending following a significant strategic investment of up to $90 million from Medtronic and a concurrent public offering, which has sparked varied community reactions. While the Medtronic backing is widely viewed as a strong industry endorsement for its innovative DurAVR technology and potential for serious growth, concerns about substantial share dilution from the offering are also actively debated among investors. This comes as the company advances its global pivotal trial for the DurAVR heart valve, targeting the multi-billion-dollar TAVR market.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending following positive Phase 1 clinical trial data for its eczema drug, soquelitinib, which showed significant efficacy and safety, particularly in treatment-resistant patients. This promising development has fueled speculation about its blockbuster potential and future partnerships, even as the company's recent public offering sparks debate among investors regarding potential dilution versus funding for accelerated pipeline progression. The community is actively discussing the drug's strong profile and the ongoing battle between bulls and bears as the stock experiences substantial volatility.

TE Connectivity Plc is a company that engages in the provision of connectivity and sensor solutions for the purpose of distribution of power, signal, and data. It operates under the following segments: Transportation Solutions, Industrial Solutions, and Communications Solutions. The Transportation Solutions segment include terminals and connector systems and components, sensors, relays, antennas, and application tooling. The Industrial Solutions segment include terminals and connector systems and components, interventional medical components, relays, heat shrink tubing, and wire and cable. The Communications Solutions segment include terminals and connector systems and components, antennas, and heat shrink tubing. The company was founded in 2007 and is headquartered in Galway, Ireland.

TE Connectivity plc - Registered Shares

TE Connectivity Ltd - Registered Shares

TE Connectivity is trending following its robust fiscal Q1 earnings, which significantly exceeded expectations for both revenue and EPS, coupled with an optimistic outlook for the coming quarter. The community is highlighting the company's record orders and strong execution in high-growth areas like AI, next-gen vehicles, and energy infrastructure, leading to a largely bullish sentiment among analysts and investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dynasty Wealth Management LLC Takes $1.02 Million Position in Merck & Co., Inc. $MRK

Dynasty Wealth Management LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange...

<ul class="summary-bullets"><li>BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares.</li><li>The update followed the release of five-year follow-up results for the Intismeran vaccine used alongside Keytruda in melanoma patients.</li><li>Moderna and Merck said additional data from the study will be shared at an upcoming medical meeting.</li></ul>Moderna Inc. shares were in focus on Wednesday after Bank of America Securities (BofA) raised its price target on the stock following new long-term data from the company’s experimental skin cancer vaccine developed with Merck, while keeping a bearish rating in place.Merck shares rose 0.6% in regular trading before slipping 0.6% after hours, while Moderna climbed 2.8% during the session and edged 0.2% lower in extended trading.<h2 class="st-heading-2">Price Target Raised, Rating Maintained</h2>BofA raised its price target on Moderna to $27 from $24 and reiterated an ‘Underperform’ rating on the shares. However, based on Moderna’s last closing price of $43, the updated target&nbsp;still implies about a 37% downside.The firm said the increase followed the release of five-year data for Intismeran Autogene, Moderna’s personalized cancer vaccine, used in combination with Merck’s Keytruda in patients with high-risk melanoma.While noting some upside potential, the brokerage pointed to challenges seen in similar combination treatments in the past, logistical challenges, and a “higher bar for success.” BofA said the higher price target reflects increased sales expectations for the vaccine in patients who have undergone surgery for melanoma.<h2 class="st-heading-2">Five-Year Skin Cancer Results</h2>Moderna and Merck said the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">latest follow-up</a> showed the vaccine combination continued to help patients remain cancer-free for longer than Keytruda alone.After five years, patients who received the combination saw a 49% lower risk of the cancer returning or leading to death than those treated with Keytruda by itself. The companies said the findings build on earlier updates shared at the two-year and three-year marks. Moderna and Merck also said they plan to share additional follow-up results at an upcoming medical meeting.<h2 class="st-heading-2">Oncology Pipeline Progress</h2>“Now with five years of follow-up data, today's results highlight the potential of a prolonged benefit of the intismeran autogene and Keytruda combination in patients with resected high-risk melanoma,” said Kyle Holen, Moderna’s head of oncology development.Holen said the company continues to invest in cancer research and is preparing for several upcoming milestones, including results from a late-stage melanoma study being run with Merck, as well as progress across eight ongoing studies in different cancer types. Meanwhile, Merck’s head of oncology, Marjorie Green, said the long-term results are encouraging for patients&nbsp;at high risk of the disease returning after surgery.Moderna said it is continuing to expand its cancer treatment work alongside its vaccine business. The company and Merck are currently running or enrolling studies across several cancers, including lung, bladder, kidney, and melanoma, as part of their joint development program for the vaccine.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘neutral’ for Moderna and ‘bearish’ for Merck, with both seeing ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_65694a07b3.webp" alt="mrna ss.png" width="969" height="140"><figcaption>MRNA sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/mrk_ss_png_42eb55ab2c.webp" alt="mrk ss.png" width="961" height="141"><figcaption>MRK sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> has risen 26% over the past 12 months, while Merck’s stock has jumped 16% over the same period.&nbsp;On Wall Street, analysts are largely neutral on MRNA, according to Koyfin data: 17 out of 24 analysts covering the stock recommend a ‘hold’ rating, while four have a ‘buy’ or ‘strong buy’ conviction, and the rest have a ‘sell’ rating. Their consensus price target of $​​36.75 leaves MRNA trading at a more than 14% premium.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious

BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges.

Equity

Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, TD Cowen Analyst Says

TD Cowen raised their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a "hold" rating in a research report on Tuesday...

<ul class="summary-bullets"><li>The clinically meaningful improvement in recurrence-free survival builds on the analyses conducted at about two years of follow-up as well as three years of follow-up.</li><li>Moderna and Merck said that they now plan to present further data from the follow-up at an upcoming medical meeting.</li><li>Moderna is currently seeking to pivot into oncology and rare-disease therapeutics.</li></ul>Moderna (MRNA) and Merck (MRK) said on Tuesday that their intismeran autogene vaccine based on messenger RNA (mRNA), in combination with cancer drug Keytruda, reduced the risk of recurrence or death by 49% in certain patients with high-risk melanoma on five years of follow-up when compared to Keytruda alone.The improvement was <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=7585547225835569&amp;symbol=MRNA">observed</a> in patients with stage III/IV melanoma who had complete removal of their tumors. Melanoma is a serious form of skin cancer characterized by the uncontrolled growth of pigment-producing cells.Moderna and Merck said that they now plan to present further data from the follow-up at an upcoming medical meeting.<h2 class="st-heading-2">Executives’ Take</h2>The clinically meaningful improvement in recurrence-free survival builds on the analyses conducted at about two years of follow-up, as well as three years of follow-up, the companies said."We continue to invest in our platform in oncology because of encouraging outcomes like these, which illustrate mRNA's potential in cancer care. We look forward to several additional milestones to come, including the results of our Phase 3 study in adjuvant melanoma in collaboration with Merck, and continued progress across the eight Phase 2 and Phase 3 studies in multiple tumor types and patient populations," Moderna's Senior Vice President and Head of Development of Oncology and Therapeutics Kyle Holen said.Moderna is currently seeking to pivot into oncology and rare-disease therapeutics. "Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics," CEO Stéphane Bancel <a href="https://stocktwits.com/news-articles/markets/equity/moderna-procures-1.5-billion-loan-to-grow-its-pipeline-beyond-vaccines/cLPA0dfREaR">said</a> in November.Investment in late-stage oncology and rare disease programs will set the company up for additional growth in 2027 and 2028, as per the firm.Shares of MRNA traded 1.1% higher at the time of writing while MRK stock traded marginally in the red.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRNA stock fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume dipped from ‘extremely high’ to ‘high’ levels.Meanwhile, sentiment around MRK shares stayed within the ‘neutral’ territory, coupled with ‘normal’ message volume.A Stocktwits user opined that the news is “solid” for Moderna’s oncology segment.<stembedurl>https://www.stocktwits.com/MobyOneCanobi/message/642290058</stembedurl>Another user voiced hopes for the stock crossing the $50/share price this week.<stembedurl>https://www.stocktwits.com/Raven67/message/642288562</stembedurl><a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained 18% over the past 12 months while <a href="https://stocktwits.com/symbol/MRK">MRK shares</a> have gained 13%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mu-stock-analyst-target-hikes-how-much-upside-does-retail-expect/cmUuYEzR4Ob">MU Stock Garners Attention Amid Analyst Target Hikes — How Much Upside Does Retail Expect?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update

Intismeran autogene vaccine, in combination with cancer drug Keytruda, reduced the risk of recurrence or death at five years of follow-up, the company said. 

Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?

Gardasil's sharp sales slump in China and Japan puts Merck under pressure heading into Q4 earnings, with the vaccine's sales expected to stay under strain.

Turtle Creek Wealth Advisors LLC Cuts Position in Merck & Co., Inc. $MRK

Turtle Creek Wealth Advisors LLC lowered its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 68.1% during the 3rd quarter, according to its most recent filing with the Securities & Exchange...

CytomX Stock Rises 31% in a Month: Here's What You Should Know

CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.

NorthCrest Asset Manangement LLC Buys 81,276 Shares of Merck & Co., Inc. $MRK

NorthCrest Asset Manangement LLC lifted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 52.9% during the 3rd quarter, according to the company in its most recent 13F filing...

Wealth Enhancement Advisory Services LLC Acquires 98,009 Shares of Merck & Co., Inc. $MRK

Wealth Enhancement Advisory Services LLC increased its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 5.9% in the third quarter, according to its most recent Form 13F filing with the...

Winners & Losers: The ETF Playbook to Glide Trump's Great Healthcare Plan

Trump's Great Healthcare Plan redraws healthcare winners and losers - here's how ETFs like IHE could benefit as middlemen face pressure.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MRK News

MRKMerck & Co Inc